Autoimmunity is a hallmark of post-COVID syndrome
Autoimmunity has emerged as a characteristic of the post-COVID syndrome (PCS), which may be related to sex. In order to further investigate the relationship between SARS-CoV-2 and autoimmunity in PCS, a clinical and serological assessment on 100 patients was done. Serum antibody profiles against sel...
Saved in:
| Published in | Journal of translational medicine Vol. 20; no. 1; pp. 129 - 5 |
|---|---|
| Main Authors | , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
BioMed Central Ltd
16.03.2022
BioMed Central BMC |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Autoimmunity has emerged as a characteristic of the post-COVID syndrome (PCS), which may be related to sex. In order to further investigate the relationship between SARS-CoV-2 and autoimmunity in PCS, a clinical and serological assessment on 100 patients was done. Serum antibody profiles against self-antigens and infectious agents were evaluated by an antigen array chip for 116 IgG and 104 IgM antibodies. Thirty pre-pandemic healthy individuals were included as a control group. The median age of patients was 49 years (IQR: 37.8 to 55.3). There were 47 males. The median post-COVID time was 219 (IQR: 143 to 258) days. Latent autoimmunity and polyautoimmunity were found in 83% and 62% of patients, respectively. Three patients developed an overt autoimmune disease. IgG antibodies against IL-2, CD8B, and thyroglobulin were found in more than 10% of the patients. Other IgG autoantibodies, such as anti-interferons, were positive in 5–10% of patients. Anti-SARS-CoV-2 IgG antibodies were found in > 85% of patients and were positively correlated with autoantibodies, age, and body mass index (BMI). Few autoantibodies were influenced by age and BMI. There was no effect of gender on the over- or under-expression of autoantibodies. IgG anti-IFN-λ antibodies were associated with the persistence of respiratory symptoms. In summary, autoimmunity is characteristic of PCS, and latent autoimmunity correlates with humoral response to SARS-CoV-2. |
|---|---|
| AbstractList | Autoimmunity has emerged as a characteristic of the post-COVID syndrome (PCS), which may be related to sex. In order to further investigate the relationship between SARS-CoV-2 and autoimmunity in PCS, a clinical and serological assessment on 100 patients was done. Serum antibody profiles against self-antigens and infectious agents were evaluated by an antigen array chip for 116 IgG and 104 IgM antibodies. Thirty pre-pandemic healthy individuals were included as a control group. The median age of patients was 49 years (IQR: 37.8 to 55.3). There were 47 males. The median post-COVID time was 219 (IQR: 143 to 258) days. Latent autoimmunity and polyautoimmunity were found in 83% and 62% of patients, respectively. Three patients developed an overt autoimmune disease. IgG antibodies against IL-2, CD8B, and thyroglobulin were found in more than 10% of the patients. Other IgG autoantibodies, such as anti-interferons, were positive in 5-10% of patients. Anti-SARS-CoV-2 IgG antibodies were found in > 85% of patients and were positively correlated with autoantibodies, age, and body mass index (BMI). Few autoantibodies were influenced by age and BMI. There was no effect of gender on the over- or under-expression of autoantibodies. IgG anti-IFN-λ antibodies were associated with the persistence of respiratory symptoms. In summary, autoimmunity is characteristic of PCS, and latent autoimmunity correlates with humoral response to SARS-CoV-2. Autoimmunity has emerged as a characteristic of the post-COVID syndrome (PCS), which may be related to sex. In order to further investigate the relationship between SARS-CoV-2 and autoimmunity in PCS, a clinical and serological assessment on 100 patients was done. Serum antibody profiles against self-antigens and infectious agents were evaluated by an antigen array chip for 116 IgG and 104 IgM antibodies. Thirty pre-pandemic healthy individuals were included as a control group. The median age of patients was 49 years (IQR: 37.8 to 55.3). There were 47 males. The median post-COVID time was 219 (IQR: 143 to 258) days. Latent autoimmunity and polyautoimmunity were found in 83% and 62% of patients, respectively. Three patients developed an overt autoimmune disease. IgG antibodies against IL-2, CD8B, and thyroglobulin were found in more than 10% of the patients. Other IgG autoantibodies, such as anti-interferons, were positive in 5-10% of patients. Anti-SARS-CoV-2 IgG antibodies were found in > 85% of patients and were positively correlated with autoantibodies, age, and body mass index (BMI). Few autoantibodies were influenced by age and BMI. There was no effect of gender on the over- or under-expression of autoantibodies. IgG anti-IFN-[lambda] antibodies were associated with the persistence of respiratory symptoms. In summary, autoimmunity is characteristic of PCS, and latent autoimmunity correlates with humoral response to SARS-CoV-2. Keywords: Post-COVID syndrome, Post-COVID, Long COVID, Post-acute COVID-19, COVID-19, Autoimmunity, Autoantibodies, Latent autoimmunity, Antigen array Abstract Autoimmunity has emerged as a characteristic of the post-COVID syndrome (PCS), which may be related to sex. In order to further investigate the relationship between SARS-CoV-2 and autoimmunity in PCS, a clinical and serological assessment on 100 patients was done. Serum antibody profiles against self-antigens and infectious agents were evaluated by an antigen array chip for 116 IgG and 104 IgM antibodies. Thirty pre-pandemic healthy individuals were included as a control group. The median age of patients was 49 years (IQR: 37.8 to 55.3). There were 47 males. The median post-COVID time was 219 (IQR: 143 to 258) days. Latent autoimmunity and polyautoimmunity were found in 83% and 62% of patients, respectively. Three patients developed an overt autoimmune disease. IgG antibodies against IL-2, CD8B, and thyroglobulin were found in more than 10% of the patients. Other IgG autoantibodies, such as anti-interferons, were positive in 5–10% of patients. Anti-SARS-CoV-2 IgG antibodies were found in > 85% of patients and were positively correlated with autoantibodies, age, and body mass index (BMI). Few autoantibodies were influenced by age and BMI. There was no effect of gender on the over- or under-expression of autoantibodies. IgG anti-IFN-λ antibodies were associated with the persistence of respiratory symptoms. In summary, autoimmunity is characteristic of PCS, and latent autoimmunity correlates with humoral response to SARS-CoV-2. Autoimmunity has emerged as a characteristic of the post-COVID syndrome (PCS), which may be related to sex. In order to further investigate the relationship between SARS-CoV-2 and autoimmunity in PCS, a clinical and serological assessment on 100 patients was done. Serum antibody profiles against self-antigens and infectious agents were evaluated by an antigen array chip for 116 IgG and 104 IgM antibodies. Thirty pre-pandemic healthy individuals were included as a control group. The median age of patients was 49 years (IQR: 37.8 to 55.3). There were 47 males. The median post-COVID time was 219 (IQR: 143 to 258) days. Latent autoimmunity and polyautoimmunity were found in 83% and 62% of patients, respectively. Three patients developed an overt autoimmune disease. IgG antibodies against IL-2, CD8B, and thyroglobulin were found in more than 10% of the patients. Other IgG autoantibodies, such as anti-interferons, were positive in 5-10% of patients. Anti-SARS-CoV-2 IgG antibodies were found in > 85% of patients and were positively correlated with autoantibodies, age, and body mass index (BMI). Few autoantibodies were influenced by age and BMI. There was no effect of gender on the over- or under-expression of autoantibodies. IgG anti-IFN-λ antibodies were associated with the persistence of respiratory symptoms. In summary, autoimmunity is characteristic of PCS, and latent autoimmunity correlates with humoral response to SARS-CoV-2.Autoimmunity has emerged as a characteristic of the post-COVID syndrome (PCS), which may be related to sex. In order to further investigate the relationship between SARS-CoV-2 and autoimmunity in PCS, a clinical and serological assessment on 100 patients was done. Serum antibody profiles against self-antigens and infectious agents were evaluated by an antigen array chip for 116 IgG and 104 IgM antibodies. Thirty pre-pandemic healthy individuals were included as a control group. The median age of patients was 49 years (IQR: 37.8 to 55.3). There were 47 males. The median post-COVID time was 219 (IQR: 143 to 258) days. Latent autoimmunity and polyautoimmunity were found in 83% and 62% of patients, respectively. Three patients developed an overt autoimmune disease. IgG antibodies against IL-2, CD8B, and thyroglobulin were found in more than 10% of the patients. Other IgG autoantibodies, such as anti-interferons, were positive in 5-10% of patients. Anti-SARS-CoV-2 IgG antibodies were found in > 85% of patients and were positively correlated with autoantibodies, age, and body mass index (BMI). Few autoantibodies were influenced by age and BMI. There was no effect of gender on the over- or under-expression of autoantibodies. IgG anti-IFN-λ antibodies were associated with the persistence of respiratory symptoms. In summary, autoimmunity is characteristic of PCS, and latent autoimmunity correlates with humoral response to SARS-CoV-2. Autoimmunity has emerged as a characteristic of the post-COVID syndrome (PCS), which may be related to sex. In order to further investigate the relationship between SARS-CoV-2 and autoimmunity in PCS, a clinical and serological assessment on 100 patients was done. Serum antibody profiles against self-antigens and infectious agents were evaluated by an antigen array chip for 116 IgG and 104 IgM antibodies. Thirty pre-pandemic healthy individuals were included as a control group. The median age of patients was 49 years (IQR: 37.8 to 55.3). There were 47 males. The median post-COVID time was 219 (IQR: 143 to 258) days. Latent autoimmunity and polyautoimmunity were found in 83% and 62% of patients, respectively. Three patients developed an overt autoimmune disease. IgG antibodies against IL-2, CD8B, and thyroglobulin were found in more than 10% of the patients. Other IgG autoantibodies, such as anti-interferons, were positive in 5-10% of patients. Anti-SARS-CoV-2 IgG antibodies were found in > 85% of patients and were positively correlated with autoantibodies, age, and body mass index (BMI). Few autoantibodies were influenced by age and BMI. There was no effect of gender on the over- or under-expression of autoantibodies. IgG anti-IFN-[lambda] antibodies were associated with the persistence of respiratory symptoms. In summary, autoimmunity is characteristic of PCS, and latent autoimmunity correlates with humoral response to SARS-CoV-2. |
| ArticleNumber | 129 |
| Audience | Academic |
| Author | Ramírez-Santana, Carolina Acosta-Ampudia, Yeny Zhu, Chengsong Li, Quan-Zhen Rojas, Manuel Monsalve, Diana M. Rodríguez, Yhojan Anaya, Juan-Manuel |
| Author_xml | – sequence: 1 givenname: Manuel surname: Rojas fullname: Rojas, Manuel – sequence: 2 givenname: Yhojan surname: Rodríguez fullname: Rodríguez, Yhojan – sequence: 3 givenname: Yeny surname: Acosta-Ampudia fullname: Acosta-Ampudia, Yeny – sequence: 4 givenname: Diana M. surname: Monsalve fullname: Monsalve, Diana M. – sequence: 5 givenname: Chengsong surname: Zhu fullname: Zhu, Chengsong – sequence: 6 givenname: Quan-Zhen surname: Li fullname: Li, Quan-Zhen – sequence: 7 givenname: Carolina surname: Ramírez-Santana fullname: Ramírez-Santana, Carolina – sequence: 8 givenname: Juan-Manuel orcidid: 0000-0002-6444-1249 surname: Anaya fullname: Anaya, Juan-Manuel |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35296346$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kktr3DAUhUVJaR7tH-iiGLrpxqnej01hmL4GAtm03YprSZ4ota2pZQfm31cTJyVTStFC4uqcT1fcc45OhjQEhF4TfEmIlu8zoUaqGlNaY8aorvkzdEa4MrXQSp48OZ-i85xvMaZccPMCnTJRnIzLM0RW85Ri389DnPZVzBVUN9B1PYw_q9RWu5Snen39Y_OxyvvBj6kPL9HzFrocXj3sF-j750_f1l_rq-svm_XqqnaCiakOoGijWg_Sa9_IFiimrVOAlfCgPG1FAM1daDgRguhACHCQHIAzykig7AJtFq5PcGt3Yyw97W2CaO8LadxaGKfoumCxNqYR0jPCOBdKGmUYdoJwo5wwGgrrw8LazU0fvAvDNEJ3BD2-GeKN3aY7qw3liskCePcAGNOvOeTJ9jG70HUwhDRnSyXHZQLl6SJ9u0i3UFqLQ5sK0R3kdiWNEZxyeQBe_kNVlg99dGXObSz1I8Obp1_40_vjKItALwI3ppzH0FoXJ5hiOvwodpZge0iNXVJjS2rsfWosL1b6l_WR_h_Tb9ppwZI |
| CitedBy_id | crossref_primary_10_1016_j_amjms_2024_04_010 crossref_primary_10_1093_braincomms_fcad092 crossref_primary_10_3389_fnano_2022_987117 crossref_primary_10_4049_immunohorizons_2400033 crossref_primary_10_56294_piii2024328 crossref_primary_10_1016_j_jaci_2023_02_008 crossref_primary_10_3390_diagnostics13111850 crossref_primary_10_3389_fimmu_2023_1177691 crossref_primary_10_1007_s10456_023_09885_6 crossref_primary_10_1002_jmv_28864 crossref_primary_10_25122_jml_2022_0329 crossref_primary_10_3389_fsysb_2024_1422384 crossref_primary_10_3389_fimmu_2023_1243689 crossref_primary_10_3389_fimmu_2022_1070994 crossref_primary_10_4103_bjhs_bjhs_42_23 crossref_primary_10_1111_jce_16117 crossref_primary_10_47360_1995_4484_2023_397_420 crossref_primary_10_1186_s12889_024_19543_1 crossref_primary_10_3390_microorganisms12050909 crossref_primary_10_1016_j_jsmc_2023_10_012 crossref_primary_10_1016_j_jaut_2023_103070 crossref_primary_10_1186_s12933_022_01623_4 crossref_primary_10_1136_jnnp_2023_332073 crossref_primary_10_1080_14647273_2023_2262757 crossref_primary_10_1016_j_ajem_2023_09_051 crossref_primary_10_1093_brain_awad155 crossref_primary_10_1016_j_cyto_2024_156688 crossref_primary_10_1038_s41538_024_00261_2 crossref_primary_10_1016_j_jtauto_2023_100204 crossref_primary_10_22141_2224_0551_19_5_2024_1728 crossref_primary_10_3389_fimmu_2022_945021 crossref_primary_10_3748_wjg_v30_i37_4104 crossref_primary_10_1042_BCJ20220154 crossref_primary_10_20411_pai_v8i1_572 crossref_primary_10_4103_ecdt_ecdt_6_24 crossref_primary_10_1016_j_isci_2023_106935 crossref_primary_10_1136_bcr_2022_253735 crossref_primary_10_1002_jmv_28524 crossref_primary_10_1016_j_acci_2024_05_001 crossref_primary_10_3390_pathogens11070800 crossref_primary_10_1371_journal_pbio_3001709 crossref_primary_10_3389_fimmu_2024_1341843 crossref_primary_10_3390_v15030675 crossref_primary_10_1016_j_jare_2024_11_011 crossref_primary_10_1093_infdis_jiac106 crossref_primary_10_3389_fphys_2023_1203472 crossref_primary_10_1016_j_jaut_2023_103132 crossref_primary_10_1016_j_tmaid_2023_102606 crossref_primary_10_1136_bmj_2023_074937 crossref_primary_10_47360_1995_4484_2024_32_54 crossref_primary_10_3390_ijms24021335 crossref_primary_10_1007_s11886_024_02087_6 crossref_primary_10_1172_JCI176466 crossref_primary_10_1212_NXI_0000000000200216 crossref_primary_10_1016_j_intimp_2024_111599 crossref_primary_10_1016_j_pmr_2023_04_008 crossref_primary_10_3390_microorganisms11092301 crossref_primary_10_1055_a_2009_3541 crossref_primary_10_1080_23744235_2024_2389481 crossref_primary_10_1017_neu_2024_10 crossref_primary_10_1038_s41598_024_56462_y crossref_primary_10_3390_v15020400 crossref_primary_10_1038_s41514_023_00118_0 crossref_primary_10_1016_j_jaut_2024_103267 crossref_primary_10_1038_s41598_023_48502_w crossref_primary_10_3389_fimmu_2022_981532 crossref_primary_10_3390_pharmaceutics16060835 crossref_primary_10_3390_ijms242417198 crossref_primary_10_1016_j_bcp_2024_116066 crossref_primary_10_1016_j_autrev_2023_103409 crossref_primary_10_3389_fimmu_2023_1117464 crossref_primary_10_1080_1744666X_2022_2085561 crossref_primary_10_1038_s41598_022_20849_6 crossref_primary_10_1016_j_autrev_2023_103402 crossref_primary_10_1111_sji_13344 crossref_primary_10_1007_s12181_024_00722_8 crossref_primary_10_1186_s12902_023_01296_4 crossref_primary_10_1002_jmv_29887 crossref_primary_10_56083_RCV3N2_026 crossref_primary_10_1007_s41030_023_00224_0 crossref_primary_10_1002_jmv_29001 crossref_primary_10_15789_2220_7619_AMG_10359 crossref_primary_10_1002_jmv_28273 crossref_primary_10_1111_sji_13313 crossref_primary_10_15212_AMM_2023_0004 crossref_primary_10_7326_M24_0737 crossref_primary_10_1007_s00112_023_01782_y crossref_primary_10_1089_jir_2022_0193 crossref_primary_10_4081_jbr_2024_12567 crossref_primary_10_1016_j_ajmo_2024_100068 crossref_primary_10_1016_j_jtauto_2025_100280 crossref_primary_10_7759_cureus_43600 crossref_primary_10_1038_s41467_022_32507_6 crossref_primary_10_3390_jcm12144659 crossref_primary_10_1111_1744_9987_13974 crossref_primary_10_3389_fimmu_2023_1322818 crossref_primary_10_3390_ijms241310458 crossref_primary_10_3928_19382359_20220913_06 crossref_primary_10_1007_s00431_023_05360_y crossref_primary_10_1007_s10067_023_06670_0 crossref_primary_10_1093_oxfimm_iqad002 crossref_primary_10_1016_j_rmcr_2024_102017 crossref_primary_10_1136_rmdopen_2023_003022 crossref_primary_10_15252_emmm_202217341 crossref_primary_10_1016_j_cytogfr_2024_08_002 crossref_primary_10_3390_biom14070835 |
| Cites_doi | 10.1016/j.jtauto.2021.100091 10.1093/infdis/jiac017 10.1016/j.jtauto.2022.100140 10.1126/sciimmunol.abl4340 10.1186/s12967-021-03184-8 10.1016/j.jaut.2017.07.003 10.1016/j.autrev.2011.10.004 10.1186/s12967-020-02464-z 10.1016/j.autrev.2021.102947 10.1186/s12967-020-02524-4 10.1038/s41467-021-25509-3 |
| ContentType | Journal Article |
| Copyright | 2022. The Author(s). COPYRIGHT 2022 BioMed Central Ltd. The Author(s) 2022 |
| Copyright_xml | – notice: 2022. The Author(s). – notice: COPYRIGHT 2022 BioMed Central Ltd. – notice: The Author(s) 2022 |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM DOA |
| DOI | 10.1186/s12967-022-03328-4 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) Open Access资源_DOAJ |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic CrossRef |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1479-5876 |
| EndPage | 5 |
| ExternalDocumentID | oai_doaj_org_article_0899b56d3134457697930c51497c598a PMC8924736 A699542466 35296346 10_1186_s12967_022_03328_4 |
| Genre | Letter Comment Research Support, Non-U.S. Gov't |
| GeographicLocations | Colombia |
| GeographicLocations_xml | – name: Colombia |
| GrantInformation_xml | – fundername: Universidad del Rosario grantid: ABN011/IV-FBG001 – fundername: ; grantid: ABN011/IV-FBG001 |
| GroupedDBID | --- 0R~ 29L 2WC 53G 5VS 6PF 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAWTL AAYXX ABDBF ABUWG ACGFO ACGFS ACIHN ACIWK ACPRK ACUHS ADBBV ADUKV AEAQA AENEX AFKRA AFPKN AFRAH AHBYD AHMBA AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CITATION CS3 DIK DU5 E3Z EBD EBLON EBS ESX F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IHR INH INR ITC KQ8 M1P M48 M~E O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO RBZ RNS ROL RPM RSV SBL SOJ TR2 TUS UKHRP WOQ WOW XSB ~8M -A0 3V. ACRMQ ADINQ C24 CGR CUY CVF ECM EIF NPM PMFND 7X8 PJZUB PPXIY 5PM PUEGO |
| ID | FETCH-LOGICAL-c535t-ea72b7fda6d8db6fa202fc7a075da7d2f5ea84ceb415518e11a4a64aa43231e23 |
| IEDL.DBID | M48 |
| ISSN | 1479-5876 |
| IngestDate | Wed Aug 27 01:26:05 EDT 2025 Thu Aug 21 13:42:36 EDT 2025 Thu Aug 07 15:17:46 EDT 2025 Tue Jun 17 21:45:46 EDT 2025 Tue Jun 10 20:43:36 EDT 2025 Thu Jan 02 22:54:29 EST 2025 Thu Apr 24 23:07:04 EDT 2025 Tue Jul 01 02:59:35 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Autoimmunity COVID-19 Post-COVID Autoantibodies Post-COVID syndrome Latent autoimmunity Antigen array Long COVID Post-acute COVID-19 |
| Language | English |
| License | 2022. The Author(s). Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c535t-ea72b7fda6d8db6fa202fc7a075da7d2f5ea84ceb415518e11a4a64aa43231e23 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Correspondence-1 ObjectType-Commentary-3 content type line 23 |
| ORCID | 0000-0002-6444-1249 |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.1186/s12967-022-03328-4 |
| PMID | 35296346 |
| PQID | 2640328769 |
| PQPubID | 23479 |
| PageCount | 5 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_0899b56d3134457697930c51497c598a pubmedcentral_primary_oai_pubmedcentral_nih_gov_8924736 proquest_miscellaneous_2640328769 gale_infotracmisc_A699542466 gale_infotracacademiconefile_A699542466 pubmed_primary_35296346 crossref_citationtrail_10_1186_s12967_022_03328_4 crossref_primary_10_1186_s12967_022_03328_4 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2022-03-16 |
| PublicationDateYYYYMMDD | 2022-03-16 |
| PublicationDate_xml | – month: 03 year: 2022 text: 2022-03-16 day: 16 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London |
| PublicationTitle | Journal of translational medicine |
| PublicationTitleAlternate | J Transl Med |
| PublicationYear | 2022 |
| Publisher | BioMed Central Ltd BioMed Central BMC |
| Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central – name: BMC |
| References | J-M Anaya (3328_CR3) 2021; 4 W-T Ma (3328_CR8) 2017; 83 GJ Tobón (3328_CR9) 2012; 11 Y Acosta-Ampudia (3328_CR1) 2022; 1 Y Liu (3328_CR5) 2021; 19 3328_CR7 P Bastard (3328_CR4) 2021; 6 L Camacho-Domínguez (3328_CR10) 2022; 1 A De Lorenzo (3328_CR11) 2020; 18 D Maguire (3328_CR12) 2020; 18 SE Chang (3328_CR2) 2021; 12 J-M Anaya (3328_CR6) 2021; 20 34965855 - J Transl Med. 2021 Dec 30;19(1):524 |
| References_xml | – volume: 4 start-page: 100091 year: 2021 ident: 3328_CR3 publication-title: J Transl Autoimmun. doi: 10.1016/j.jtauto.2021.100091 – ident: 3328_CR7 – volume: 1 start-page: jiac017 year: 2022 ident: 3328_CR1 publication-title: J Infect Dis. doi: 10.1093/infdis/jiac017 – volume: 1 start-page: 10014.0 year: 2022 ident: 3328_CR10 publication-title: J Transl Autoimmun. doi: 10.1016/j.jtauto.2022.100140 – volume: 6 start-page: 1 year: 2021 ident: 3328_CR4 publication-title: Sci Immunol. doi: 10.1126/sciimmunol.abl4340 – volume: 19 start-page: 524 year: 2021 ident: 3328_CR5 publication-title: J Transl Med doi: 10.1186/s12967-021-03184-8 – volume: 83 start-page: 95 year: 2017 ident: 3328_CR8 publication-title: J Autoimmun doi: 10.1016/j.jaut.2017.07.003 – volume: 11 start-page: 259 year: 2012 ident: 3328_CR9 publication-title: Autoimmun Rev. doi: 10.1016/j.autrev.2011.10.004 – volume: 18 start-page: 299 year: 2020 ident: 3328_CR11 publication-title: J Transl Med doi: 10.1186/s12967-020-02464-z – volume: 20 start-page: 102947 year: 2021 ident: 3328_CR6 publication-title: Autoimmun Rev. doi: 10.1016/j.autrev.2021.102947 – volume: 18 start-page: 354 year: 2020 ident: 3328_CR12 publication-title: J Transl Med doi: 10.1186/s12967-020-02524-4 – volume: 12 start-page: 5417 year: 2021 ident: 3328_CR2 publication-title: Nat Commun doi: 10.1038/s41467-021-25509-3 – reference: 34965855 - J Transl Med. 2021 Dec 30;19(1):524 |
| SSID | ssj0024549 |
| Score | 2.605577 |
| Snippet | Autoimmunity has emerged as a characteristic of the post-COVID syndrome (PCS), which may be related to sex. In order to further investigate the relationship... Abstract Autoimmunity has emerged as a characteristic of the post-COVID syndrome (PCS), which may be related to sex. In order to further investigate the... |
| SourceID | doaj pubmedcentral proquest gale pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 129 |
| SubjectTerms | Adult Antibodies, Viral - blood Autoimmunity COVID-19 Demographic aspects Health aspects Humans Immunoglobulin M - blood Long COVID Male Middle Aged Post-acute COVID-19 Post-COVID Post-COVID syndrome SARS-CoV-2 |
| SummonAdditionalLinks | – databaseName: Open Access资源_DOAJ dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LT9wwELYQB9RLVaClAYqChNQDikhsx06OWyhakJZeoOJmTWxHXRUSxGYP_Htm8lhthNReuMa2bM_DMxN7vmHsROQZ6LTIIi9jF0lXxKhzVkelFyp3heU5UKA4u1HTO3l9n96vlfqiN2EdPHBHuDO6lipS5UQipETnOEeBii2a-VzbFCei0xdt3hBMDSh7GPYMKTKZOlugVcMDgV6ux0LQ_6SRGWrR-t-eyWtGafxgcs0CXX5iH3vXMZx0S95mG77aYVuz_nJ8lyWTZVPP23yP5iWcL0IIqVLKIzz_DesyfKoXTXT-6_fVRTjAFHxmd5c_b8-nUV8RIbKpSJvIg-aFLh0ol1H-HPCYl1YD2n0H2vEy9ZBJ6wvZIq35JAEJSgJIgX6c5-IL26zqyn9lIboGygFB3cSAhFXghdQy9j4HnsWlC1gyEMjYHi6cqlY8mDZsyJTpiGqQqKYlqpEBO12NeerAMv7Z-wfRfdWTgK7bD8h-07Pf_I_9AftOXDOkjrg8C31WAW6SgK3MRBHgHZdKBexw1BPVyI6ajwe-G2qit2eVr5cLgy4jgQ7i3AHb6-RgtWZB19ZC4mg9kpDRpsYt1fxPi-KdYeSrhdp_DyocsA-8E-4oUYdss3le-m_oLDXFUasXr3oGCzc priority: 102 providerName: Directory of Open Access Journals |
| Title | Autoimmunity is a hallmark of post-COVID syndrome |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/35296346 https://www.proquest.com/docview/2640328769 https://pubmed.ncbi.nlm.nih.gov/PMC8924736 https://doaj.org/article/0899b56d3134457697930c51497c598a |
| Volume | 20 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lb9QwEB71ISEuiHdTyipISBxQIIkdOzkgtFtaFaQtqGLRiovlOA6saJOyyUr03zPjTZZGVIhLDrGd2OMZz-fXNwDPWZZqmeRpYHlYBLzIQ7Q5I4PSMpEVuYkzTRPF6ak4mfEP82S-BX24o06AzY1TO4onNVuev_r18-otGvwbZ_CpeN2gz0Jzp3PpIWO0WrQNu-iZJEU0mPL0D_de4uBwxGUWJDgM9JdobvzGwFE5Pv-_R-1rbmt4pPKajzq-C3c6cOmP19pwD7ZsdR9uTbvt8wcQjVdtvXA3Qtorf9H42qdYKhd6-cOvS_-ybtrg8OOX9-_8nsjgIcyOjz4fngRdzITAJCxpA6tlnMuy0KJI6YadjsO4NFIjMii0LOIysTrlxubccbHZKNJcC641Z4j0bMwewU5VV3YPfAQPotBEhhNqjjhLW8YlD63NdJyGZeFB1AtImY5QnOJanCs3sUiFWgtVoVCVE6riHrzclLlc02n8M_eE5L7JSVTY7kW9_KY6y1K0b5knomARw1pKkeGIExrEgZk0CWqiBy-o1xSpEFbP6O7eATaSqK_UWBAlXsyF8OBgkBMNzQySn_X9riiJTqdVtl41CkEl0RLivz14vNaDTZ0ZbWwzjqXlQEMGjRqmVIvvjuc7xbmxZGL_P_77BG7Ha90NInEAO-1yZZ8iWmrzEWzLuRzB7uTo9NPZyK05jJxZ4PNs8vU3wvcQtA |
| linkProvider | Scholars Portal |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Autoimmunity+is+a+hallmark+of+post-COVID+syndrome&rft.jtitle=Journal+of+translational+medicine&rft.au=Rojas%2C+Manuel&rft.au=Rodr%C3%ADguez%2C+Yhojan&rft.au=Acosta-Ampudia%2C+Yeny&rft.au=Monsalve%2C+Diana+M&rft.date=2022-03-16&rft.issn=1479-5876&rft.eissn=1479-5876&rft.volume=20&rft.issue=1&rft.spage=129&rft_id=info:doi/10.1186%2Fs12967-022-03328-4&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1479-5876&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1479-5876&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1479-5876&client=summon |